Cytokine Response in Sepsis: Diagnostic, Prognostic, and Therapeutic Implications

Year 2025, Volume: 15 Issue: 3, 193 - 200, 31.12.2025

Agil Balakishiyev , Dürdane Kuruca , Levent Ertugrul

https://doi.org/10.26650/experimed.1678274

Abstract

The Sepsis-3 definition characterizes sepsis as an organ dysfunction that is life-threatening and induced by a maladaptive host response to infection. Analyses conducted by the World Health Organization on the global disease burden suggest that sepsis contributes to nearly one-fifth of worldwide deaths, highlighting its sustained prominence as a major concern in contemporary healthcare. The pathogenesis of sepsis involves complex molecular pathways that remain to be elucidated, particularly regarding immunological mechanisms. Extensive clinical research in the literature has examined the correlation between plasma cytokine profiles and sepsis prognosis, mortality, and morbidity. In current therapeutic approaches, cytokine absorption systems are widely employed to control hypercytokinemia. This comprehensive review critically evaluates existing research on cytokine-mediated pathways in sepsis pathogenesis, with particular emphasis on the molecular mechanisms and the therapeutic potential of cytokine modulation strategies based on contemporary evidence.

Keywords

Sepsis , Septic shock , Cytokine , immune response

References

• 1. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the global burden of disease study. Lancet 2020; 395: 200-11.
• 2. Farrah K, McIntyre L, Doig CJ, Talarico R, Taljaard M, Krahn M, et al. Sepsis-associated mortality, resource use, and healthcare costs: a propensity-matched cohort study. Crit Care Med 2021; 49: 215-27.
• 3. Machado FR, Cavalcanti AB, Bozza FA, Ferreira EM, Angotti Carrara FS, Sousa JL, et al. The epidemiology of sepsis in Brazilian intensive care units (the Sepsis PREvalence Assessment Database, SPREAD): an observational study. Lancet Infect Dis 2017; 17: 1180-9.
• 4. Prescott HC, Osterholzer JJ, Langa KM, Angus DC, Iwashyna TJ. Late mortality after sepsis: propensity matched cohort study. BMJ 2016; 353: i2375.
• 5. Jentzer JC, Lawler PR, Houten HKV, Yao X, Kashani KB, Dunlay SM. Cardiovascular events among survivors of sepsis hospitalization: a retrospective cohort analysis. J Am Heart Assoc 2023; 12: e027813.
• 6. Torio CM, Moore BJ. National inpatient hospital costs: the most expensive conditions by payer, 2013. 2016 May. In: Healthcare cost and utilization project (HCUP) statistical briefs. Rockville (MD): Agency for healthcare research and quality (US); 2006 Feb–. Statistical Brief #204.
• 7. David S, Brunkhorst FM. Sepsis-3 : Was ist gesichert in der therapie? [Sepsis-3 : What has been confirmed in therapy?]. Internist (Berl). 2017; 58(12): 1264-71.
• 8. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
• 9. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315: 801-10.
• 10. Bauer M, Gerlach H, Vogelmann T, Preissing F, Stiefel J, Adam D. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019- results from a systematic review and meta-analysis. Crit Care 2020; 24: 239.
• 11. Shankar-Hari M, Rubenfeld GD. Population enrichment for critical care trials: phenotypes and differential outcomes. Curr Opin Crit Care 2019; 25: 489-97.
• 12. Wang W, Liu C-F. Sepsis heterogeneity. World J Pediatr 2023; 19: 919-27.
• 13. Gårdlund B, Dmitrieva NO, Pieper CF, Finfer S, Marshall JC, Taylor Thompson B. Six subphenotypes in septic shock: Latent class analysis of the PROWESS Shock study. J Crit Care 2018; 47: 70-9.
• 14. Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA 2020; 323: 1478-87.
• 15. Cicchinelli S, Pignataro G, Gemma S, Piccioni A, Picozzi D, Ojetti V, et al. PAMPs and DAMPs in sepsis: A review of their molecular features and potential clinical implications. Int J Mol Sci 2024; 25: 962.
• 16. Li D, Wu M. Pattern recognition receptors in health and diseases. Signal Transduct Target Ther 2021; 6(1): 291.
• 17. Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly and localization of Tolllike receptor signalling complexes. Nature Rev Immunol 2014; 14: 546-58.
• 18. Yuan S, Jiang S-C, Zhang Z-W, Fu Y-F, Hu J, Li Z-L. Quantification of cytokine storms during virus infections. Front Immunol 2021; 12: 659419.
• 19. Alexander AF, Kelsey I, Forbes H, Miller-Jensen K. Single-cell secretion analysis reveals a dual role for IL-10 in restraining and resolving the TLR4-induced inflammatory response. Cell Rep 2021; 36: 109728.
• 20. Gottschalk RA, Martins AJ, Angermann BR, Dutta B, Ng CE, Uderhardt S, et al. Distinct NF-κB and MAPK activation thresholds uncouple steady-state microbe sensing from anti-pathogen inflammatory responses. Cell Syst 2016; 2: 378-90.
• 21. Pennock ND, White JT, Cross EW, Cheney EE, Tamburini BA, Kedl RM. T cell responses: naïve to memory and everything in between. Adv Physiol Educ 2013; 37: 273-83.
• 22. Černý J, Stříž I. Adaptive innate immunity or innate adaptive immunity? Clin Sci 2019; 133: 1549-65.
• 23. Dong X, Wang C, Liu X, Gao W, Bai X, Li Z. Lessons learned comparing immune system alterations of bacterial sepsis and SARS-CoV-2 sepsis. Front Immunol 2020; 11: 598404
• 24. McElvaney OJ, McEvoy NL, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM, et al. Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med 2020; 202: 812-21.
• 25. Brodin P, Jojic V, Gao T, Bhattacharya S, Angel CJ, Furman D, et al. Variation in the human immune system is largely driven by non-heritable influences. Cell 2015; 160: 37-47.
• 26. Spierenburg EAJ, Portengen L, Smit LAM, Krop EJM, Hylkema MN, Rijkers GT, et al. Stability of individual LPS-induced ex vivo cytokine release in a whole blood assay over a five-year interval. J Immunol Methods 2018; 460: 119-24.
• 27. van der Poll T, Shankar-Hari M, Wiersinga WJ. The immunology of sepsis. Immunity 2021; 54: 2450-64.
• 28. van Vught LA, Wiewel MA, Hoogendijk AJ, Frencken JF, Scicluna BP, Klein Klouwenberg PMC, et al. The host response in patients with sepsis developing intensive care unit-acquired secondary infections. Am J Respir Crit Care Med 2017; 196: 458-70.
• 29. Brady J, Horie S, Laffey JG. Role of the adaptive immune response in sepsis. Intensive Care Med Exp 2020; 8(Suppl 1): 20.
• 30. Bedet A, Razazi K, Boissier F, Surenaud M, Hue S, Giraudier S, et al. Mechanisms of thrombocytopenia during septic shock: a multiplex cluster analysis of endogenous sepsis mediators. Shock 2018; 49: 641-8.
• 31. Li J, Rong L, Cui R, Feng J, Jin Y, Chen X, et al. Dynamic changes in serum IL-6, IL-8, and IL-10 predict the outcome of ICU patients with severe COVID-19. Ann Palliat Med 2021; 10: 3706-14.
• 32. Fajgenbaum DC, June CH. Cytokine storm. N Eng J Med 2020; 383: 2255-73.
• 33. Daviaud F, Grimaldi D, Dechartres A, Charpentier J, Geri G, Marin N, et al. Timing and causes of death in septic shock. Ann Intensive Care 2015; 5: 16.
• 34. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med 2021; 49: e1063-e143.
• 35. Fong KM, Au SY, Ng GWY. Steroid, ascorbic acid, and thiamine in adults with sepsis and septic shock: a systematic review and component network metaanalysis. Sci Rep 2021; 11: 15777.
• 36. Friesecke S, Träger K, Schittek GA, Molnar Z, Bach F, Kogelmann K, et al. International registry on the use of the CytoSorb® adsorber in ICU patients : Study protocol and preliminary results. Med Klin Intensivmed Notfmed 2019; 114: 699-707.
• 37. Brandenburg K, Ferrer-Espada R, Martinez-de-Tejada G, Nehls C, Fukuoka S, Mauss K, et al. A Comparison between SARS-CoV-2 and gram-negative bacteria-induced hyperinflammation and sepsis. Int J Mol Sci 2023; 24(20): 15169.
• 38. Jarczak D, Kluge S, Nierhaus A. Sepsis-pathophysiology and therapeutic concepts. Front Med (Lausanne) 2021; 8: 628302.
• 39. Chang K, Svabek C, Vazquez-Guillamet C, Sato B, Rasche D, Wilson S, et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care 2014; 18: R3.
• 40. Leśnik P, Janc J, Mierzchala-Pasierb M, Tański W, Wierciński J, Łysenko L. Interleukin-7 and interleukin-15 as prognostic biomarkers in sepsis and septic shock: Correlation with inflammatory markers and mortality. Cytokine 2023; 169: 156277.
• 41. Daix T, Mathonnet A, Brakenridge S, Dequin P-F, Mira J-P, Berbille F, et al. Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial. Ann Intensive Care 2023; 13(1): 17.
• 42. Basheer M, Saad E, Kananeh M, Asad L, Khayat O, Badarne A, et al. Cytokine patterns in COVID-19 patients: which cytokines predict mortality and which protect against? Curr Issues Mol Biol 2022; 44: 4735-47.
• 43. Liu D, Huang SY, Sun JH, Zhang HC, Cai QL, Gao C, et al. Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options. Mil Med Res 2022; 9: 56.
• 44. Maneta E, Aivalioti E, Tual-Chalot S, Emini Veseli B, Gatsiou A, Stamatelopoulos K, et al. Endothelial dysfunction and immunothrombosis in sepsis. Front Immunol 2023; 14: 1144229.
• 45. Sonneville R, Benghanem S, Jeantin L, de Montmollin E, Doman M, Gaudemer A, et al. The spectrum of sepsis-associated encephalopathy: a clinical perspective. Crit Care 2023; 27(1): 386.
• 46. Ibarra-Estrada M, Kattan E, Aguilera-González P, Sandoval-Plascencia L, Rico-Jauregui U, Gómez-Partida CA, et al. Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. Crit Care 2023; 27(1): 110.
• 47. Komorowski M, Green A, Tatham KC, Seymour C, Antcliffe D. Sepsis biomarkers and diagnostic tools with a focus on machine learning. EBioMedicine 2022; 86: 104394.
• 48. Song J, Park DW, Moon S, Cho H-J, Park JH, Seok H, et al. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions. BMC Infec Dis 2019; 19(1): 968.
• 49. Yu B, Chen M, Zhang Y, Cao Y, Yang J, Wei B, et al. Diagnostic and prognostic value of interleukin-6 in emergency department sepsis patients. Infect Drug Resist 2022; 15: 5557-66.
• 50. Gharamti AA, Samara O, Monzon A, Montalbano G, Scherger S, DeSanto K, et al. Proinflammatory cytokines levels in sepsis and healthy volunteers, and tumor necrosis factor-alpha associated sepsis mortality: A systematic review and meta-analysis. Cytokine 2022; 158: 156006.